Abstract:<p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p><p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p>

Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Epidemiological Characteristics and Management of Nonalcoholic Fatty Liver Disease/nonalcoholic Steatohepatitis in China: A Narrative Review

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey

Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis

Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study.

Non‐alcoholic fatty liver disease (NAFLD) in Asia—More efforts are needed

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China

Burden of Liver Complications Related to Non‐alcoholic Fatty Liver Disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019

General Characteristics and Clinical Practices of Chinese Patients with Non-Alcoholic Fatty Liver Disease

[Advances in epidemiology and serum markers for the noninvasive diagnosis of nonalcoholic fatty liver disease].

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review

Low Docosahexaenoic Acid Content in Plasma Phospholipids is Associated with Increased Non-alcoholic Fatty Liver Disease in China

Prevalence of Nonalcoholic Fatty Liver Disease and Economy

Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Office Employees in Beijing, China

Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China

The Prevalence and Risk Factors on Different Degrees of Non-Alcoholic Fatty Liver Disease in Shanghai